Research programme: platelet ADP receptor antagonists - PfizerAlternative Names: BX 667
Latest Information Update: 26 Mar 2010
At a glance
- Originator Berlex
- Developer Pfizer
- Class Piperazines
- Mechanism of Action Platelet ADP receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Thrombosis